Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis

Takafumi Yanagisawa; Fahad Quhal; Tatsushi Kawada; Kensuke Bekku; Ekaterina Laukhtina; Pawel Rajwa; Markus Von Deimling; Marcin Chlosta; Benjamin Pradere; Pierre I. Karakiewicz; Keiichiro Mori; Takahiro Kimura; Manuela Schmidinger; Shahrokh F. Shariat

doi:10.2217/imt-2023-0039

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis

Takafumi Yanagisawa, Fahad Quhal, Tatsushi Kawada, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Markus Von Deimling, Marcin Chlosta, Benjamin Pradere, Pierre I. Karakiewicz, Keiichiro Mori, Takahiro Kimura, Manuela Schmidinger, Shahrokh F. Shariat

University Hospital

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.

Original language	English
Pages (from-to)	1309-1322
Number of pages	14
Journal	Immunotherapy
Volume	15
Issue number	15
DOIs	https://doi.org/10.2217/imt-2023-0039
Publication status	Published - Oct 1 2023

Keywords

age
ICI
immune checkpoint inhibitors
metastasis
renal cell carcinoma
tyrosine kinase inhibitors

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2023-0039

Cite this

Yanagisawa, T., Quhal, F., Kawada, T., Bekku, K., Laukhtina, E., Rajwa, P., Deimling, M. V., Chlosta, M., Pradere, B., Karakiewicz, P. I., Mori, K., Kimura, T., Schmidinger, M., & Shariat, S. F. (2023). Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis. Immunotherapy, 15(15), 1309-1322. https://doi.org/10.2217/imt-2023-0039

Yanagisawa, T, Quhal, F, Kawada, T , Bekku, K, Laukhtina, E, Rajwa, P, Deimling, MV, Chlosta, M, Pradere, B, Karakiewicz, PI, Mori, K, Kimura, T, Schmidinger, M & Shariat, SF 2023, 'Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis', Immunotherapy, vol. 15, no. 15, pp. 1309-1322. https://doi.org/10.2217/imt-2023-0039

@article{7ca922105ac04c7ab5e684052fd2d596,

title = "Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis",

abstract = "Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.",

keywords = "age, ICI, immune checkpoint inhibitors, metastasis, renal cell carcinoma, tyrosine kinase inhibitors",

author = "Takafumi Yanagisawa and Fahad Quhal and Tatsushi Kawada and Kensuke Bekku and Ekaterina Laukhtina and Pawel Rajwa and Deimling, {Markus Von} and Marcin Chlosta and Benjamin Pradere and Karakiewicz, {Pierre I.} and Keiichiro Mori and Takahiro Kimura and Manuela Schmidinger and Shariat, {Shahrokh F.}",

note = "Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

month = oct,

day = "1",

doi = "10.2217/imt-2023-0039",

language = "English",

volume = "15",

pages = "1309--1322",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "15",

}

TY - JOUR

T1 - Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC

T2 - A meta-analysis

AU - Yanagisawa, Takafumi

AU - Quhal, Fahad

AU - Kawada, Tatsushi

AU - Bekku, Kensuke

AU - Laukhtina, Ekaterina

AU - Rajwa, Pawel

AU - Deimling, Markus Von

AU - Chlosta, Marcin

AU - Pradere, Benjamin

AU - Karakiewicz, Pierre I.

AU - Mori, Keiichiro

AU - Kimura, Takahiro

AU - Schmidinger, Manuela

AU - Shariat, Shahrokh F.

PY - 2023/10/1

Y1 - 2023/10/1

N2 - Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.

AB - Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.

KW - age

KW - ICI

KW - immune checkpoint inhibitors

KW - metastasis

KW - renal cell carcinoma

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85171900339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171900339&partnerID=8YFLogxK

U2 - 10.2217/imt-2023-0039

DO - 10.2217/imt-2023-0039

M3 - Review article

C2 - 37694583

AN - SCOPUS:85171900339

SN - 1750-743X

VL - 15

SP - 1309

EP - 1322

JO - Immunotherapy

JF - Immunotherapy

IS - 15

ER -

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this